R5XA.F ACELRX PHARMACEUT. DL-01
- Market cap
- EUR 48.5M
- P/E
- -
- P/B
- 3.82x
- ROE
- -95.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is R5XA.F undervalued?
Graham numberThe Graham number of ACELRX PHARMACEUT. DL-01 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ACELRX PHARMACEUT. DL-01 fundamental analysis
No fundamental analysis for ACELRX PHARMACEUT. DL-01 yet.
ACELRX PHARMACEUT. DL-01 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ACELRX PHARMACEUT. DL-01
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory d…
Full company profileACELRX PHARMACEUT. DL-01 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ACELRX PHARMACEUT. DL-01 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 2.82M | 0.00 | 651K | 0.00 | 28.0K | 0.00 |
| Gross Profit | -935K | -820K | - | - | - | - |
| Operating Income | -36.0M | -20.4M | -16.9M | -15.3M | -13.5M | -15.7M |
| EBITDA | - | 61.9M | -9.84M | -12.6M | -14.4M | -15.7M |
| Net Income | -35.1M | 47.8M | -18.4M | -13.0M | -14.3M | -13.7M |
| EPS | -5.13 | 5.79 | -1.09 | -0.76 | -0.29 | -0.26 |
| Balance Sheet | ||||||
| Total Assets | 77.9M | 47.5M | 20.4M | 18.2M | 29.7M | 26.8M |
| Total Liabilities | 114M | 25.7M | 6.29M | 10.2M | 12.7M | 12.4M |
| Shareholders' Equity | -35.9M | 21.8M | 14.1M | 8.00M | 17.0M | 14.4M |
| Cash & Short-term Investments | 7.66M | 15.3M | 5.72M | 8.86M | 5.89M | 742K |
| Cash Flow | ||||||
| Operating Cash Flow | -30.0M | -28.3M | -17.5M | -12.7M | -11.4M | -14.6M |
| Capital Expenditure | 1.83M | 364K | 100K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -31.8M | -28.7M | -17.6M | -12.7M | -11.4M | -14.6M |
| Ratios | ||||||
| ROE | - | 218.9% | -130.4% | -162.5% | -83.9% | -95.3% |
| ROA | -45.1% | 100.6% | -90.2% | -71.3% | -48.1% | -51.2% |
| Net Profit Margin | -1,245.5% | - | -2,826.0% | - | -51,035.7% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ACELRX PHARMACEUT. DL-01 dividends
ACELRX PHARMACEUT. DL-01 has not paid dividends in the last 5 fiscal years.
Last stock split: 1:20 on Oct 26, 2022.
Who owns ACELRX PHARMACEUT. DL-01
- Insiders 21.41%
- Institutions 46.11%
- Public & others 32.48%
- Shares outstanding 51.9M
- Free float 25.5M
ACELRX PHARMACEUT. DL-01 company profile
- Company name
- ACELRX PHARMACEUT. DL-01
- Ticker
- R5XA.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 12
- Fiscal year end
- December
- Address
- 1850 Gateway Drive, San Mateo, CA, United States, 94404
- Phone
- 650 216 3500
- Website
- talphera.com
About ACELRX PHARMACEUT. DL-01
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
ACELRX PHARMACEUT. DL-01 management
4- Mr. Vincent J. AngottiCEO & Director · born 1968
- Mr. Raffi Mark AsadorianChief Financial Officer · born 1969
- Dr. Shakil Aslam M.D.Chief Medical Officer · born 1965
- Mr. Anil N. DasuChief Engineering Officer · born 1963